The China Securities Regulatory Commission has approved Luozhou Stock's registration for listing on the Growth Enterprise Market (GEM).
On June 18, the China Securities Regulatory Commission issued the approval for Luoyang Bearing Group Co., Ltd. to proceed with its initial public offering of shares.
On June 18, the China Securities Regulatory Commission released the "Approval of Luoyang Bearing Group Co., Ltd.'s Initial Public Offering of Stocks." It is reported that Luoyang Bearing Group plans to be listed on the ChiNext board of the Shenzhen Stock Exchange, with China Securities Co., Ltd. as its sponsor, aiming to raise 1.8 billion yuan.
According to the prospectus, Luoyang Bearing Group's main business is research and development, production, and sales of bearings and related components. It is one of the largest comprehensive bearing manufacturing enterprises in the Chinese bearing industry. The company has been deeply involved in the bearing industry for many years, with outstanding technological innovation capabilities. It owns the only national key laboratory in the bearing industry and is in a leading position in research and layout in the high-end bearing field in the country.
The company's product series includes over 30,000 types, with product sizes ranging from 6mm to 15m in inner diameter, widely used in major equipment, high-end equipment, and strategic emerging industries such as new energy vehicles.
Related Articles

From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.

Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.

One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.

Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.

One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)

RECOMMEND





